Targeting PNPLA3 I148M variant in MASLD: Cell-type specific mechanisms and precision therapy opportunities

Area of Science:

• Hepatology
• Genetics
• Molecular Biology

Background:

• The PNPLA3 I148M variant is a major genetic risk factor for metabolic dysfunction-associated steatotic liver disease (MASLD).
• This variant contributes to liver disease progression through lipotoxicity in hepatocytes and hepatic stellate cells (HSCs).

Purpose of the Study:

• To review the lipotoxicity mechanisms of the PNPLA3 I148M variant.
• To summarize therapeutic strategies targeting this genetic factor in MASLD.

Main Methods:

• Review of existing literature on PNPLA3 I148M function and MASLD pathogenesis.
• Analysis of the molecular mechanisms underlying lipotoxicity, oxidative stress, and cell death pathways.

Main Results:

• The mutant PNPLA3 protein exhibits reduced triglyceride hydrolysis, altered lipid profiles, and resistance to degradation, leading to lipid accumulation.
• Lipid peroxidation, mitochondrial dysfunction, ER stress, and ferroptosis in hepatocytes, alongside HSC activation and fibrogenesis, contribute to the progression from steatosis to MASH.
• The I148M variant exacerbates MASLD-associated oxidative stress.

Conclusions:

• The PNPLA3 I148M variant's lipotoxicity is central to MASLD progression.
• Targeting the mechanisms driven by this variant offers a promising avenue for personalized MASLD therapies.